These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
70 related items for PubMed ID: 15683027
1. [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria]. Liern M, Dieguez SM, De Reyes V, Vallejos G, Canepa C. Nefrologia; 2004; 24(6):553-8. PubMed ID: 15683027 [Abstract] [Full Text] [Related]
2. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM. Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176 [Abstract] [Full Text] [Related]
3. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Am J Nephrol; 2002 Jul; 22(4):356-62. PubMed ID: 12169868 [Abstract] [Full Text] [Related]
4. Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency. Mackie FE, Meyer TW, Campbell DJ. Kidney Int; 2002 Feb; 61(2):555-63. PubMed ID: 11849396 [Abstract] [Full Text] [Related]
5. [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome]. Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M. Cas Lek Cesk; 1999 Oct 20; 138(18):560-4. PubMed ID: 10596472 [Abstract] [Full Text] [Related]
6. Losartan and enalapril are comparable in reducing proteinuria in children. Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C. Kidney Int; 2012 Oct 20; 82(7):819-26. PubMed ID: 22739977 [Abstract] [Full Text] [Related]
7. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE. J Pediatr; 2003 Jul 20; 143(1):89-97. PubMed ID: 12915830 [Abstract] [Full Text] [Related]
8. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. Seeman T, Pohl M, Misselwitz J, John U. Kidney Blood Press Res; 2009 Jul 20; 32(6):440-4. PubMed ID: 20016211 [Abstract] [Full Text] [Related]
9. Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydłowska W. Med Sci Monit; 2005 Apr 20; 11(4):PI31-7. PubMed ID: 15795705 [Abstract] [Full Text] [Related]
10. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat. Erman A, Veksler S, Gafter U, Boner G, Wittenberg C, van Dijk DJ. J Renin Angiotensin Aldosterone Syst; 2004 Sep 20; 5(3):146-51. PubMed ID: 15526251 [Abstract] [Full Text] [Related]
11. Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Caletti MG, Balestracci A, Missoni M, Vezzani C. Pediatr Nephrol; 2013 May 20; 28(5):745-50. PubMed ID: 23250713 [Abstract] [Full Text] [Related]
12. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis. Renke M, Tylicki L, Rutkowski P, Rutkowski B. Scand J Urol Nephrol; 2004 May 20; 38(5):427-33. PubMed ID: 15764256 [Abstract] [Full Text] [Related]
13. Angiotensin blockade as sole treatment for proteinuric kidney disease in children. Chandar J, Abitbol C, Montané B, Zilleruelo G. Nephrol Dial Transplant; 2007 May 20; 22(5):1332-7. PubMed ID: 17299000 [Abstract] [Full Text] [Related]
14. Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Zhou X, Matavelli LC, Ono H, Frohlich ED. Am J Physiol Renal Physiol; 2005 Oct 20; 289(4):F871-9. PubMed ID: 15900021 [Abstract] [Full Text] [Related]
15. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. Hoque R, Rahman MS, Iqbal M. Bangladesh Med Res Counc Bull; 2009 Aug 20; 35(2):44-8. PubMed ID: 20120778 [Abstract] [Full Text] [Related]
16. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Agarwal R. Am J Physiol Renal Physiol; 2003 Apr 20; 284(4):F863-9. PubMed ID: 12505865 [Abstract] [Full Text] [Related]
17. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies. Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z. Am J Physiol Renal Physiol; 2005 Oct 20; 289(4):F880-90. PubMed ID: 15942045 [Abstract] [Full Text] [Related]
18. Antiproteinuric effects of enalapril and losartan: a pilot study. White CT, Macpherson CF, Hurley RM, Matsell DG. Pediatr Nephrol; 2003 Oct 20; 18(10):1038-43. PubMed ID: 12920631 [Abstract] [Full Text] [Related]
19. Angiotensin II inhibition attenuates postexercise proteinuria in rats. Gündüz F, Kuru O, Sentürk UK. Int J Sports Med; 2005 Nov 20; 26(9):710-3. PubMed ID: 16237614 [Abstract] [Full Text] [Related]
20. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Abe M, Okada K, Maruyama T, Matsumoto K. Pharmacotherapy; 2009 Sep 20; 29(9):1061-72. PubMed ID: 19698011 [Abstract] [Full Text] [Related] Page: [Next] [New Search]